Avalo Therapeutics, Inc. (AVTX)
NASDAQ: AVTX · Real-Time Price · USD
18.51
-0.51 (-2.66%)
May 15, 2026, 11:30 AM EDT - Market open

Avalo Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
May '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
49433678748192
Market Cap Growth
830.98%332.09%966.44%-84.65%-75.21%-3.16%
Enterprise Value
425.85237.86-56.74-0.1253.77170
Last Close Price
18.5118.167.439.101209.604896.00
PE Ratio
--3.11-0.36-0.08-1.14-2.05
PS Ratio
8607.455698.16176.433.792.6335.52
PB Ratio
6.864.050.581.00-4.358.31
P/TBV Ratio
952.642.930.420.35-30.787.50
P/FCF Ratio
--6.53-1.59-0.24-1.77-2.70
P/OCF Ratio
--6.53-1.59-0.24-1.78-2.70
EV/Sales Ratio
7217.744031.45-128.66-0.062.9831.49
EV/EBITDA Ratio
--3.280.830.00-1.44-2.11
EV/EBIT Ratio
--3.260.830.00-1.44-2.07
EV/FCF Ratio
--4.621.160.00-2.00-2.39
Debt / Equity Ratio
-000-1.781.42
Debt / EBITDA Ratio
-----0.52-0.41
Debt / FCF Ratio
-----0.72-0.46
Net Debt / Equity Ratio
-1.20-1.18-1.01-1.01-0.57-0.94
Net Debt / EBITDA Ratio
1.041.361.970.27-0.170.27
Net Debt / FCF Ratio
1.371.912.740.24-0.230.31
Asset Turnover
0.000.000.010.070.320.09
Inventory Turnover
---128.40118.4172.73
Quick Ratio
7.077.6019.331.640.682.99
Current Ratio
7.668.1419.961.820.743.11
Return on Equity (ROE)
-111.97%-72.43%-50.06%1747.11%-684.77%-354.08%
Return on Assets (ROA)
-73.32%-54.70%-80.05%-100.67%-65.97%-132.20%
Return on Invested Capital (ROIC)
-1382.40%-989.70%-741.24%-419.07%-761.49%-981.77%
Return on Capital Employed (ROCE)
-82.54%-58.98%-85.56%-198.00%-104.61%-184.87%
Earnings Yield
-16.69%-32.16%-281.43%-1248.13%-87.88%-48.77%
FCF Yield
-11.75%-15.31%-63.05%-422.68%-56.48%-37.03%
Buyback Yield / Dilution
-131.03%-78.82%-2599.19%0.00%-686.02%-39.42%
Total Shareholder Return
-131.03%-78.82%-2599.19%0.00%-686.02%-39.42%
Updated May 13, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q